Form 4: ATAI Life Sciences CFO Anne Nagengast Johnson Sells Shares to Cover Tax Obligations

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., sold 33,545 common shares on March 21, 2025, to cover tax liabilities arising from the vesting of restricted stock units.

Summary

• On March 21, 2025, Anne Nagengast Johnson, the Chief Financial Officer of ATAI Life Sciences N.V., sold 33,545 common shares.
• The shares were sold at a price of $1.35 per share.
• This transaction was executed to satisfy the reporting person's tax liability related to the vesting of restricted stock units.
• Following the transaction, Johnson directly owns 140,045 common shares of ATAI Life Sciences N.V.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports a routine transaction to cover tax liabilities.

Industry Context

This is a routine Form 4 filing, indicating a transaction by a company insider. Such filings are common and provide transparency into the trading activities of company executives.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the stated reason for the sale.

Key Dates

Keywords

ATAI Life Sciences, Form 4, Insider Trading, Share Sale, CFO, Anne Nagengast Johnson, Tax Liability, Restricted Stock Units